重要内容提示： 证券代码：002915 证券简称：中欣氟材 公告编号：2025-017 浙江中欣氟材股份有限公司 关于2025年度为全资子公司或控股子公司提供担保 额度预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江中欣氟材股份有限公司（以下简称"公司"或"中欣氟材"）本次为全资子 公司福建中欣氟材高宝科技有限公司（以下简称"高宝科技"）和控股子公司江西 中欣埃克盛新材料有限公司（以下简称"江西埃克盛"）分别提供担保，合计担保 额度不超过人民币 5 亿元人民币，占最近一期经审计的归属于上市公司股东净资 产的比例为 38.50%；本次担保对象高宝科技和江西埃克盛的资产负债率均未超 过 70%。 浙江中欣氟材股份有限公司于 2025 年 4 月 18 日召开的第六届董事会第二十 次会议和第六届监事会第十七次会议审议通过了《关于 2025 年度为全资子公司 或控股子公司提供担保额度预计的议案》，该议案尚需提交公司 2024 年年度股 东大会审议批准。现将相关事项公告如下： 一、担保情况概述 根据公司经营发展的需要，2025 年度公司预计为公司合并报表 ...

2024 年度监事会工作报告 2024 年，浙江中欣氟材股份有限公司（以下简称"公司"）监事会认真履 行《中华人民共和国公司法》《浙江中欣氟材股份有限公司章程》等赋予的各项 职责，坚持规范运作、科学决策，认真贯彻执行股东大会的各项决议，勤勉尽责 地开展各项工作，推动公司持续、稳定、健康发展。具体工作情况报告如下： 一、2024 年公司监事会工作情况 2024 年公司监事会依照相关的法律法规，认真履行监事会的各项职责及权 利，并积极推进股东大会、董事会及监事会等管理程序的规范、实施与落实。全 年公司依法召开了监事会会议 5 次，先后审议通过了《关于公司符合向特定对象 发行股票条件的议案》《2023 年年度报告及其摘要》《2023 年度监事会工作报 告》等共 32 项议案，10 项子议案。2024 年监事会会议及决议情况如下： | 召开时间 | 届次 | 审议事项 1、《关于公司符合向特定对象发行股票条件的议案》； | | --- | --- | --- | | | | 2、《关于公司 2024 年度向特定对象发行股票方案的议案》： 2.01、发行股票的种类和面值； 2.02、发行方式和发行时间； | | | | ...

证券代码：002915 证券简称：中欣氟材 公告编号：2025-016 浙江中欣氟材股份有限公司 关于2025年度董事、监事及高级管理人员薪酬方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江中欣氟材股份有限公司（以下简称"中欣氟材"或"公司"）于 2025 年 4 月 18 日分别召开了第六届董事会第二十次会议和第六届监事会第十七次会议， 审议通过了《关于 2025 年度董事、监事及高级管理人员薪酬方案的议案》，为 进一步完善公司治理结构，强化权责利相统一、报酬与风险相对应的激励约束机 制，促进公司长期可持续发展，根据《中华人民共和国公司法》等相关法律法规、 《浙江中欣氟材股份有限公司章程》的规定，结合公司实际情况，参考行业及地 区的收入水平，公司制定了 2025 年度董事、监事及高级管理人员薪酬方案。具 体如下： 一、本方案适用对象 公司董事、监事及全体高级管理人员。 二、本方案适用期限 本方案自公司股东大会通过之日起生效，至新的薪酬方案通过股东大会审议 后失效。 三、薪酬标准 3、内部董事报酬由董事津贴和薪酬构成。津贴标准 8 万元/年，津 ...

证券代码：002915 证券简称：中欣氟材 公告编号：2025-026 浙江中欣氟材股份有限公司 关于召开2024年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江中欣氟材股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日召开第 六届董事会第二十次会议审议通过了《关于提议召开公司 2024 年年度股东大会 的议案》，决定于 2025 年 5 月 13 日召开公司 2024 年年度股东大会（以下简称"本 次股东大会"）。现将本次股东大会有关事项公告如下： 一、召开会议的基本情况 1、股东大会届次：2024 年年度股东大会 2、会议召集人：公司董事会 3、会议召开的合法、合规性：本次股东大会的召开符合有关法律、行政法 规、部门规章、规范性文件、深圳证券交易所（以下简称"深交所"）业务规则和 《公司章程》的规定。 4、会议召开时间： （1）现场会议召开时间：2025 年 5 月 13 日（星期二）下午 14:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2025 年 5 月 13 日 09:1 ...

证券代码：002915 证券简称：中欣氟材 公告编号：2025-010 浙江中欣氟材股份有限公司 第六届监事会第十七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江中欣氟材股份有限公司（以下简称"公司"）第六届监事会第十七次会议 于 2025 年 4 月 18 日在浙江省杭州市拱墅区西湖文化广场 19 号环球中心 2101 会议室以现场表决方式召开。会议通知以书面、邮件或电话方式于 2025 年 3 月 28 日向全体监事发出。应出席监事 3 名，实际出席监事 3 名。 会议由监事会主席俞伟樑先生召集并主持。本次会议的通知、召集和召开符 合《中华人民共和国公司法》（以下简称"《公司法》"）和《浙江中欣氟材股份 有限公司章程》（以下简称"《公司章程》"）的规定，会议决议合法有效。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 具体内容详见公司同日在《证券时报》《证券日报》《中国证券报》《上海证 券报》和巨潮资讯网（http://www.cninfo.com.cn）上披露的《2024 年年度报告》 和《2024 ...

浙江中欣氟材股份有限公司 第六届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 证券代码：002915 证券简称：中欣氟材 公告编号：2025-009 浙江中欣氟材股份有限公司（以下简称"公司"）第六届董事会第二十次会议 于 2025 年 4 月 18 日在浙江省杭州市拱墅区西湖文化广场 19 号环球中心 2101 会议室以现场结合通讯表决方式召开。会议通知以书面、邮件或电话方式于 2025 年 3 月 28 日向全体董事发出。应出席董事 11 名，实际出席董事 11 名，其中， 董事颜俊文先生以通讯表决的方式出席会议。 会议由董事长徐建国先生召集并主持，公司监事、高级管理人员列席了会议。 本次会议的通知、召集和召开符合《中华人民共和国公司法》（以下简称"《公司 法》"）和《浙江中欣氟材股份有限公司章程》（以下简称"《公司章程》"）的规 定，会议决议合法有效。 二、董事会会议审议情况 （一）审议并通过了《2024 年年度报告及其摘要》 表决结果：同意 11 票，反对 0 票，弃权 0 票。 本议案经公司董事会 ...

浙江中欣氟材股份有限公司 关于2024年度拟不进行利润分配的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、公司 2024 年度拟不派发现金红利，不送红股，不以资本公积金转增股本； 证券代码：002915 证券简称：中欣氟材 公告编号：2025-012 会慎重讨论，公司 2024 年度的利润分配方案为：不派发现金红利，不送红股， 不以资本公积金转增股本。 公司 2024 年度业绩出现亏损，不满足进行现金分红的条件，不属于触及《股 票上市规则》第 9.8.1 条第（九）项规定的可能被实施其他风险警示情形。 2、公司不触及《深圳证券交易所股票上市规则》9.8.1 条规定可能被实施其 他风险警示的相关情形。 一、审议程序 浙江中欣氟材股份有限公司（以下简称"中欣氟材"或"公司"）于 2025 年 4 月 18 日分别召开了第六届董事会第二十次会议和第六届监事会第十七次会议， 审议通过了《2024 年度利润分配方案》，并将该方案提交公司 2024 年年度股东 大会审议。 二、利润分配方案的基本情况 经立信会计师事务所（特殊普通合伙）审计，公司 2 ...

证券代码：002915 证券简称：中欣氟材 公告编号：2025-023 浙江中欣氟材股份有限公司 关于提请股东大会授权董事会以简易程序 向特定对象发行股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江中欣氟材股份有限公司（以下简称"中欣氟材"或"公司"）于 2025 年 4 月 18 日分别召开了第六届董事会第二十次会议和第六届监事会第十七次会议，审 议通过了《关于提请股东大会授权董事会以简易程序向特定对象发行股票的议 案》。根据《上市公司证券发行注册管理办法》《深圳证券交易所上市公司证券 发行上市审核规则》《深圳证券交易所上市公司证券发行与承销业务实施细则》 等相关规定，公司董事会提请 2024 年年度股东大会授权董事会办理以简易程序 向特定对象发行融资总额不超过人民币 3 亿元且不超过最近一年末净资产 20% 的股票，授权期限为公司 2024 年年度股东大会通过之日起至 2025 年年度股东大 会召开之日止。上述事项尚需提交股东大会审议。现将有关情况公告如下： 一、具体内容 （一）确认公司是否符合以简易程序向特定对象发行股票的条件 授权董事会 ...

Financial Performance - The company's operating revenue for 2024 was CNY 1,404,478,358.56, representing a 4.54% increase compared to CNY 1,343,528,068.38 in 2023[22]. - The net profit attributable to shareholders was a loss of CNY 185,526,314.34 in 2024, a slight improvement of 1.41% from a loss of CNY 188,179,014.98 in 2023[22]. - The cash flow from operating activities improved significantly, with a net outflow of CNY 74,765,694.92 in 2024, a 62.46% reduction from CNY 199,141,335.95 in 2023[22]. - The basic earnings per share for 2024 was -CNY 0.5682, showing a 0.98% improvement from -CNY 0.5738 in 2023[22]. - Total assets at the end of 2024 were CNY 3,193,122,766.38, a marginal increase of 0.06% from CNY 3,191,156,380.44 at the end of 2023[22]. - The company's net assets attributable to shareholders decreased by 12.49% to CNY 1,298,772,126.57 at the end of 2024, down from CNY 1,484,092,908.60 at the end of 2023[22]. - The company reported a significant loss in the fourth quarter, with a net profit attributable to shareholders of -CNY 142,531,581.18[27]. - The company achieved operating revenue of ¥1,404,478,358.56, an increase of 4.54% year-on-year[114]. - The net profit attributable to shareholders was -¥185,526,314.34, a year-on-year reduction in losses of ¥2,652,700.64[114]. Business Operations and Strategy - The company has focused on the production and R&D of fluorine-containing pharmaceutical, pesticide, and electronic material intermediates since its establishment in 2000[20]. - The company operates in the fine chemical manufacturing industry, specifically in the fluorine chemical sector[20]. - The company aims to achieve a 100% phase-out of second-generation refrigerants in the domestic market within the next five years and an 80% phase-out of third-generation refrigerants in developed countries within the next ten years[88]. - The company is actively seeking new markets and customers internationally while solidifying its existing domestic and foreign markets[90]. - The company is committed to developing functional fluorinated new materials and electronic new materials in niche markets[89]. - The company is focusing on the development of new technologies and products in the fluorine chemical sector to enhance its market position[169]. - The company is actively pursuing market expansion and strategic acquisitions to strengthen its competitive edge in the chemical industry[169]. - The company aims to become a leading domestic fluorochemical enterprise with a focus on high-end fluorine materials and a complete industrial chain by the end of 2025[172]. Research and Development - The company has maintained an annual R&D investment of approximately 4% of sales revenue, with a total of 5 invention patents and 13 utility model patents applied for during the reporting period[106]. - The company invested ¥4,309.09 million in R&D in 2024, accounting for 3.07% of total revenue, focusing on new materials and new energy technologies[121]. - The number of R&D personnel rose by 62.16% from 74 in 2023 to 120 in 2024, with a significant increase in the proportion of personnel holding bachelor's degrees by 40%[148]. - The company has developed a new synthesis process for BMMI products, improving yield and quality significantly[100]. - The company is focusing on the development of new energy electronic chemicals, including sodium hexafluorophosphate and lithium bis(fluorosulfonyl)imide, which will significantly enhance product technical content and added value[108]. Market Trends and Industry Outlook - The fluorochemical industry is projected to grow from CNY 178 billion in 2016 to CNY 323 billion by 2025, with a compound annual growth rate of 6.9%[35]. - The pharmaceutical intermediate market in China is expected to reach CNY 255.2 billion in 2024, growing at a rate of 5.45%[39]. - The global market for fluorinated pharmaceutical intermediates has been continuously growing, driven by the increasing number and proportion of fluorinated drugs, particularly in the oncology and antiviral sectors[46]. - The market for fluorinated pesticide intermediates in China reached approximately 12 billion yuan in 2023, with a year-on-year growth of 8%[57]. - The global high-performance polymer market is projected to reach $49.14 billion in 2024, with a compound annual growth rate of 8.4% from 2024 to 2029, indicating strong demand in various industries[58]. Financial Management and Governance - The company has established a governance structure that complies with relevant laws and regulations, ensuring the protection of shareholder rights[187]. - The company has implemented safety measures to mitigate risks associated with the production of flammable and toxic chemicals, although safety incidents remain a concern[181]. - The company has confirmed that there are no significant discrepancies between its governance practices and regulatory requirements[194]. - The company has established an independent financial accounting department and developed a financial management system compliant with accounting standards[198]. - The company has independent personnel management systems, ensuring that senior management does not hold positions in other companies controlled by the major shareholder[197]. Challenges and Risks - The company faces challenges from high raw material prices and a decline in product prices, impacting gross margins and operating rates[114]. - The company is exposed to raw material price volatility, which significantly affects its operating costs and profit margins[182]. - The company's customer base is concentrated in the pharmaceutical and fluorochemical sectors, with major clients including Jingxin Pharmaceutical and Zhejiang Medicine, which poses a risk if any major client faces operational difficulties[180]. - The company is facing risks related to the concentration of its products in the pharmaceutical and pesticide intermediate sectors, which could impact performance if market conditions change[180]. Environmental and Social Responsibility - The company has invested over 100 million yuan in environmental protection measures, ensuring compliance with national standards for waste emissions[181]. - The company is committed to enhancing investor relations and maintaining a positive capital image through effective communication and transparency[178].

Financial Performance - The company's revenue for Q1 2025 was CNY 355,744,197.67, representing an increase of 11.97% compared to CNY 317,726,775.95 in the same period last year[5] - Net profit attributable to shareholders was CNY 3,115,476.97, up 22.00% from CNY 2,553,569.05 year-on-year[5] - The net profit after deducting non-recurring gains and losses increased by 76.62% to CNY 2,644,913.24 from CNY 1,497,530.88 in the previous year[5] - The company experienced a 38.90% decrease in total profit, amounting to CNY 5,298,035.68, attributed to rising sales, management, and financial expenses[8] - Total operating revenue for the current period reached ¥355,744,197.67, an increase of 11.96% compared to ¥317,726,775.95 in the previous period[16] - Total operating costs amounted to ¥346,879,680.65, up from ¥303,384,589.00, reflecting a growth of 14.34%[16] - Net profit attributable to the parent company was ¥3,115,476.97, a significant increase of 22.06% from ¥2,553,569.05 in the prior period[17] - The basic and diluted earnings per share improved to ¥0.0096 from ¥0.0078, an increase of 23.08%[17] Cash Flow and Liquidity - The company's cash flow from operating activities showed a significant decline, with a net outflow of CNY 22,143,867.22 compared to a net inflow of CNY 7,179,218.34 in the same period last year, a decrease of 408.44%[5] - Cash flow from operating activities showed a net outflow of ¥22,143,867.22, contrasting with a net inflow of ¥7,179,218.34 in the previous period[18] - Cash and cash equivalents decreased to CNY 207,811,397.68 from CNY 250,629,277.56[13] - Cash and cash equivalents at the end of the period totaled ¥156,069,317.69, down from ¥209,984,130.35, indicating a decrease of 25.6%[19] - The company reported a net cash outflow from investing activities of ¥10,836,260.44, compared to a larger outflow of ¥152,485,194.09 in the previous period[18] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,236,115,236.30, reflecting a 1.35% increase from CNY 3,193,122,766.38 at the end of the previous year[5] - The company reported a total asset of CNY 3,236,115,236.30 as of March 31, 2025, an increase from CNY 3,193,122,766.38 at the beginning of the period[13] - Current assets totaled CNY 982,407,766.53, slightly up from CNY 977,915,978.58 at the start of the period[13] - Total liabilities amounted to CNY 1,693,720,736.77, up from CNY 1,657,356,153.72, showing an increase of approximately 2.2%[14] - The company’s long-term borrowings increased to CNY 391,521,065.49 from CNY 338,874,602.41, representing a growth of approximately 15.5%[14] - The total liabilities and equity reached ¥3,236,115,236.30, an increase from ¥3,193,122,766.38, representing a growth of 1.35%[15] Research and Development - The company's R&D expenses surged by 138.41% to CNY 13,840,110.45, primarily due to increased projects in subsidiaries[8] - Research and development expenses surged to ¥13,840,110.45, compared to ¥5,805,219.20, marking an increase of 138.79%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 28,620, with the largest shareholder holding 19.97% of the shares[9] - The company's equity increased significantly, with retained earnings rising to CNY 3,793,308.29 from CNY 677,831.32, marking a substantial growth[14] Other Information - The company decided to terminate the plan for issuing shares to specific targets for the year 2024[11] - The first quarter report of Zhejiang Zhongxin Fluorine Material Co., Ltd. is unaudited[20] - The new accounting standards will be implemented starting from 2025[20] - The financial statement items related to the first year of the new accounting standards will be adjusted at the beginning of the year[20] - The board of directors announced the first quarter report on April 18, 2025[20] - There are no specific performance summaries or user data provided in the document[20] - Future outlook and performance guidance are not detailed in the content[20] - No information on new products or technology development is mentioned[20] - Market expansion and mergers or acquisitions are not addressed in the document[20] - Other new strategies are not discussed in the content[20] - The document does not provide any financial figures or percentages[20]